Market closed

ResMed/$RMD

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Ticker

$RMD
Sector
Health Care

Trading on

NYSE

Industry

Health Care Equipment & Supplies
Headquarters
San Diego, United States

Employees

9,980
Website
www.resmed.com

ResMed Metrics

BasicAdvanced
$35B
27.88
$8.47
0.70
$2.02
0.90%

$35B

0.7

$263.05

$170.56

1M

$2.02

3.329

1.622

15.268

15.986

23.75%

66.70%

13.89%

25.65%

27.885

7.042

6.6

17.25

25.071

0.86%

0.90%

9.38%

40.24%

12.68%

33.57%

6.98%

What the Analysts think about ResMed

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ResMed stock.

ResMed Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ResMed Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ResMed News

AllArticlesVideos
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

GlobeNewsWire·1 day ago
Jan De Witte joins GHO Capital as Operating Partner

Jan De Witte joins GHO Capital as Operating Partner

GlobeNewsWire·2 weeks ago
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RMD

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Mar20
ResMed
Dividend·Payment
$0.53
Per share
FAQs

What’s the current market cap for ResMed stock?

ResMed (RMD) has a market cap of $35B as of February 27, 2025.

What is the P/E ratio for ResMed stock?

The price to earnings (P/E) ratio for ResMed (RMD) stock is 27.88 as of February 27, 2025.

Does ResMed stock pay dividends?

Yes, the ResMed (RMD) stock pays dividends to shareholders. As of February 27, 2025, the dividend rate is $2.02 and the yield is 0.9%. ResMed has a payout ratio of 23.76% on a trailing twelve-month basis.

When is the next ResMed dividend payment date?

The next ResMed (RMD) dividend payment is scheduled for March 20, 2025.

What is the beta indicator for ResMed?

ResMed (RMD) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.